Competitive AMPA receptor antagonists
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Glutamic acid (Glu) is the major excitatory neurotransmitter in the mammalian central nervous system (CNS) where it is involved in the physiological regulation of different processes. It has been well established that excessive endogenous Glu is associated with many acute and chronic neurodegenerative disorders such as cerebral ischaemia, epilepsy, amiotrophic lateral sclerosis, Parkinson's, and Alzheimer's disease. These data have consequently added great impetus to the research in this field. In fact, many Glu receptor antagonists acting at the N‐methyl‐D‐aspartic acid (NMDA), 2‐amino‐3‐(3‐hydroxy‐5‐methylisoxazol‐4‐yl)propionic acid (AMPA), and/or kainic acid (KA) receptors have been developed as research tools and potential therapeutic agents. Ligands showing competitive antagonistic action at the AMPA type of Glu receptors were first reported in 1988, and the systemically active 2,3‐dihydroxy‐6‐nitro‐7‐sulphamoyl‐benzo[f]quinoxaline (NBQX) was first shown to have useful therapeutic effects in animal models of neurological disease in 1990. Since then, the quinoxaline template has represented the backbone of various competitive AMPA receptor antagonists belonging to different classes which had been developed in order to increase potency, selectivity and water solubility, but also to prolong the “in vivo” action. Compounds that present better pharmacokinetic properties and less serious adverse effects with respect to the others previously developed are undergoing clinical evaluation. In the near future, the most important clinical application for the AMPA receptor antagonists will probably be as neuroprotectant in neurodegenerative diseases, such as epilepsy, for the treatment of patients not responding to current therapies. The present review reports the history of competitive AMPA receptor antagonists from 1988 up to today, providing a systematic coverage of both the open and patent literature. © 2006 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 3×
“A crucial amino acid residue in the channel pore region can be either arginine or glutamine: residue of the former is found in the GluR2, whereas the other three subunits contain the latter in the corresponding position (Q/R site) and this affects the channel electrophysiological properties.(61)”
BackgroundCoderre, T. J., Katz, J., Vaccarino, A. L., & Melzack, R. (1993) · Pain · doi:10.1016/0304-3959(93)90161-h · Cited by 1,966 · cited 1×
“The iGluRs which are present in the spinal cord play a pivotal role in pain transmission and seem to be involved in neuronal plasticity which accompanies sensitization to pain.(134,135) Inhibition of spinal iGluRs has antinociceptive effect in many animal models.”
BackgroundA Family of AMPA-Selective Glutamate Receptors
Keinänen, K., Wisden, W., Sommer, B., Werner, P., Herb, A., Verdoorn, T. A., Sakmann, B., & Seeburg, P. H. (1990) · Science · doi:10.1126/science.2166337 · Cited by 1,479
Geiger, J. R. P., Melcher, T., Koh, D.-S., Sakmann, B., Seeburg, P. H., Jonas, P., & Monyer, H. (1995) · Neuron · doi:10.1016/0896-6273(95)90076-4 · Cited by 1,260
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a Neuroprotectant for Cerebral Ischemia
Sheardown, M. J., Nielsen, E. Ø., Hansen, A. J., Jacobsen, P., & Honoré, T. (1990) · Science · doi:10.1126/science.2154034 · Cited by 1,138
Burnashev, N., Monyer, H., Seeburg, P. H., & Sakmann, B. (1992) · Neuron · doi:10.1016/0896-6273(92)90120-3 · Cited by 1,087
The Tetrameric Structure of a Glutamate Receptor Channel
Rosenmund, C., Stern-Bach, Y., & Stevens, C. F. (1998) · Science · doi:10.1126/science.280.5369.1596 · Cited by 794
Factors affecting excitatory amino acid release following severe human head injury
Bullock, R., Zauner, A., Woodward, J. J., Myseros, J., Choi, S. C., Ward, J. D., Marmarou, A., & Young, H. F. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.89.4.0507 · Cited by 526
Palmer, C. L., Cotton, L., & Henley, J. M. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.7 · Cited by 211
Cited by
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568
“There are a wealth of structurally diverse non-NMDA receptor antagonists that could be explored (Gill, 1994; Bleakman and Lodge, 1998; O’Neill et al., 1998; Elger et al., 2006; Catarzi et al., 2007).”
BackgroundSynopsis of Some Recent Tactical Application of Bioisosteres in Drug Design
Meanwell, N. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1013693 · Cited by 2,854
Environmental and health effects of the herbicide glyphosate
Van Bruggen, A. H. C., He, M. M., Shin, K., Mai, V., Jeong, K. C., Finckh, M. R., & Morris, J. G. (2018) · Science of The Total Environment · doi:10.1016/j.scitotenv.2017.10.309 · Cited by 992
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Zhao, W.-Q., Santini, F., Breese, R., Ross, D., Zhang, X. D., Stone, D. J., Ferrer, M., Townsend, M., Wolfe, A. L., Seager, M. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057182 · Cited by 188
Metadata
- Authors
- Catarzi, D., Colotta, V., & Varano, F.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2006-08-04
- Volume
- 27
- Issue
- 2
- Pages
- 239-278
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W2133987553
- Cited by
- 84
- References
- 11
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.